Shares of the clinical-stage biotech Inovio Pharmaceuticals (NASDAQ: INO) are up by a Healthy 20.3%, on abnormally high volume, as of 10:40 a.m. EDT Tuesday. Today's double-digit rally appears to be carryover from CEO Dr. Joseph Kim's presentation yesterday at the H.C. Wainwright 22nd Annual Global Investment Conference.
While Kim's presentation didn't exactly include any earth-shaking updates, he did note that a peer-reviewed paper should be forthcoming discussing the phase 1 trial results for the company's closely watched COVID-19 vaccine candidate, INO-4800. This first human trial included 40 healthy volunteers aged 18 to 50. Previously, Inovio announced that the vaccine produced either neutralizing antibodies or T-cell responses in all study participants.
Image source: Getty Images.